Merck Serono to appeal against CHMP opinion on Erbitux in NSCLC
This article was originally published in Scrip
Merck Serono has appealed against the EU CHMP's refusal to endorse Erbitux (cetuximab) for the first–line treatment of EGFR–expressing advanced non–small cell lung cancer (NSCLC) in combination with platinum–based chemotherapy.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.